The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .
An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia.
OBJECTIVES To examine the safety and efficacy of desmopressin in three doses given to women with multiple sclerosis to treat nocturia with or without enuresis . PATIENTS AND METHODS Eight women with clinical ly confirmed multiple sclerosis and nocturia with or without enuresis were entered as in- patients into an open , nonr and omized , placebo-controlled study of incremental doses of 20 , 40 and 60 micrograms desmopressin .  Urinary and serum sodium , plasma arginine vasopressin and urine osmolality were monitored every 4 h for 24 h. A single dose of placebo or desmopressin was given during each of four 24-h periods . RESULTS There was a significant decrease in nocturnal urinary volumes and a significant increase in nocturnal urinary osmolalities in patients taking desmopressin when compared with those taking a placebo , but there was no difference among the desmopressin doses . There was no significant difference in serum sodium level between the desmopressin doses . However , at the end of the 24-h period with the 60 micrograms dose , serum sodium was decreased significantly . CONCLUSIONS Neither a significant decrease in nocturnal urinary volumes nor an increase in urinary osmolality was achieved by doses of desmopressin > 20 micrograms . A dose of 60 g was associated with a decreased serum sodium level at the end of the 24-h period but there was no biochemical hyponatraemia . Because there were no benefits and a possibility of clinical hyponatraemia with higher doses , doses of > 20 micrograms desmopressin can not be recommended
The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .